<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029791</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL21_0906</org_study_id>
    <nct_id>NCT05029791</nct_id>
  </id_info>
  <brief_title>Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients</brief_title>
  <acronym>COLEMAN</acronym>
  <official_title>Study of Variations of Immune Infiltrate and Cell Plasticity Markers in Patients With Metastatic Melanoma Under Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COLEMAN is an opened prospective monocentric non-randomized study, initiated by the Hospices&#xD;
      Civils de Lyon. Population targeted are patients from 18 years old with stage III or IV&#xD;
      metastatic melanoma eligible for a metastatic melanoma treatment administered as part of&#xD;
      usual care.&#xD;
&#xD;
      The objective is to study the variations of immune infiltrate and cell plasticity before and&#xD;
      under immunotherapy or targeted therapy. Two biopsies are done before and one month after the&#xD;
      treatment initiation and one blood sample is done after the treatment initiation.&#xD;
&#xD;
      100 patients will be included and followed during 5 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2030</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD8+ T cells</measure>
    <time_frame>Month 1 before chemotherapy</time_frame>
    <description>Dosage of CD8+ T cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD8+ T cells</measure>
    <time_frame>Month 1 after chemotherapy</time_frame>
    <description>Dosage of CD8+ T cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>expression of ZEB1 protein</measure>
    <time_frame>Month 1 before chemotherapy</time_frame>
    <description>Dosage of ZEB 1 protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>expression of ZEB1 protein</measure>
    <time_frame>Month 1 after chemotherapy</time_frame>
    <description>Dosage of ZEB 1 protein</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Week 13</time_frame>
    <description>Partial or complete response as assessed by the clinician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Week 13</time_frame>
    <description>Time between the date of treatment initiation and the date of first progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Every year until 5 years</time_frame>
    <description>Time between the date of treatment initiation and the date of first progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>Week 13</time_frame>
    <description>Time between the date of treatment initiation and the patient death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>Every year until 5 years</time_frame>
    <description>Time between the date of treatment initiation and the patient death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Metastatic melanoma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with stage III or IV melanoma eligible for an immunotherapy or targeted therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tumor biopsy</intervention_name>
    <description>2 cutaneous tumor biopsies before treatment initiation (D-28 to D-1) and under treatment (Month 1)</description>
    <arm_group_label>Metastatic melanoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>1 EDTA blood sample (8mL) before treatment initiation (D-28 to D-1)</description>
    <arm_group_label>Metastatic melanoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient age ≥ 18&#xD;
&#xD;
          -  Female patients must agree to the use of 2 methods of contraception. For man one&#xD;
             method of contraception is needed if if his partner is in childbearing age throughout&#xD;
             the study and for at least 5 months after last study treatment administration.&#xD;
&#xD;
          -  Patients with metastatic stage III or IV melanoma relapse&#xD;
&#xD;
          -  Eligible for a melanoma metastatic treatment indicated and administered as part of&#xD;
             usual care&#xD;
&#xD;
          -  Patients must be willing and able to undergo cutaneous tumor biopsies (except on the&#xD;
             face and folds or lymph node) according to the study protocol&#xD;
&#xD;
          -  Patient insured or beneficiary of a health insurance plan&#xD;
&#xD;
          -  Patient able to provide informed consent and sign approved consent forms to&#xD;
             participate in the study&#xD;
&#xD;
          -  Patient accepting the conservation of biological samples and their use for clinical&#xD;
             research including genetic research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hematologic tumours under treatment&#xD;
&#xD;
          -  Patients with a documented history of autoimmune pathology&#xD;
&#xD;
          -  Ocular melanoma&#xD;
&#xD;
          -  Persons placed under the safeguard of justice&#xD;
&#xD;
          -  Use of immunosuppressants including corticosteroids 4 weeks before the inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stéphane Dalle, Pr</last_name>
    <phone>04 78 86 16 79</phone>
    <phone_ext>+33</phone_ext>
    <email>Florence.guillemaud@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Myrtille Le Bouar, MSc</last_name>
    <phone>04 78 86 15 96</phone>
    <phone_ext>+33</phone_ext>
    <email>myrtille.le-bouar@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de dermatologie (Bâtiment 1A)</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stéphane Dalle, Pr</last_name>
      <phone>04.78.86.16.79</phone>
      <phone_ext>+33</phone_ext>
      <email>stephane.dalle@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Myrtille Le Bouar, Msc</last_name>
      <phone>04 78 86 15 96</phone>
      <phone_ext>+33</phone_ext>
      <email>myrtille.le-bouar@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sarah Milley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Poulalhon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Perier-Muzet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien Debarbieux</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Luc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Immune Infiltrate</keyword>
  <keyword>Cell plasticity markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

